Metabolic consequences of erastin-induced ferroptosis in human ovarian cancer cells: an untargeted metabolomics study
Kaylie I. Kirkwood-Donelson, Alan K. Jarmusch, Carl D. Bortner, Bruce Alex Merrick, Birandra K. Sinha · 2025
Read Metabolic consequences of erastin-induced ferroptosis in human ovarian cancer cells: an untargeted metabolomics study by Kaylie I. Kirkwood-Donelson, Alan K. Jarmusch, Carl D. Bortner, Bruce Alex Merrick, Birandra K. Sinha (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11788483.txt.
Description
Kaylie Kirkwood-Donelson and co-authors chart the chemical fallout when a drug forces ovarian cancer cells into a rust-like death, in a paper whose text dates it to 2024. The drug, erastin, triggers ferroptosis, an iron-driven death fuelled by oxidative damage, attractive because resistant cancers still succumb. The team treated two ovarian cancer lines, one of them drug-resistant, and profiled hundreds of small molecules inside the cells.
Both lines drained their glutathione and cysteine, the cell's main antioxidant reserves, and built up ophthalmate, a known stress marker. Taurine, another natural antioxidant, fell too. Because both the sensitive and resistant lines reacted alike, the shared chemical signature may serve as a biomarker that ferroptosis is truly under way. Such markers would help clinicians judge whether the new death pathway is being hit in patients.
Catalog record
| CREATOR | Kaylie I. Kirkwood-Donelson, Alan K. Jarmusch, Carl D. Bortner, Bruce Alex Merrick, Birandra K. Sinha |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |